Prostate Cancer Clinical Trials in Pittsburgh

Showing 161-180 of 199 trials

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00020735

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using toremifene may fight prostate cancer by reducing the production of androgens. PURPOSE: Randomized phase II trial to study the effectiveness of toremifene followed by radical prostatectomy in treating patients who have stage I or stage II prostate cancer.

Prostate Cancer

Joel Nelson, MD45 participantsStarted Apr 2001

Pittsburgh, Pennsylvania, United States

COMPLETEDPHASE3< 1 mile

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

NCT00003162

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which radiation therapy regimen is more effective for bone metastases. PURPOSE: Randomized phase III trial to compare different radiation therapy regimens in treating patients who have bone metastases from breast or prostate cancer.

Breast CancerMetastatic CancerPain+1 more

Radiation Therapy Oncology Group949 participantsStarted Feb 1998

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Huntsville, Alabama, United States +250 more locations

Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

Prostate Cancer Trials in Other Cities

Study of Oxaliplatin and Taxotere in Prostate Cancer

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Multi-site Decision Impact Study for Decipher

Prostate Biomarker Study

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Other Conditions in Pittsburgh